Selicrelumab Biosimilar - Research Grade

Human

CD40

>1mg/ml

Human IgG2-Kappa

Anti-Mouse CD40 (FGK4.5) In Vivo Antibody - Low Endotoxin (ICH1073), Bulk Anti-Human CD40 (G28.5) Antibody (ICH1156), Dacetuzumab Biosimilar - Research Grade (ICH5030), Sotigalimab Biosimilar - Research Grade (ICH5031), Lucatumumab Biosimilar - Research Grade (ICH5129), Abiprubart Biosimilar - Research Grade (ICH5323), Bleselumab Biosimilar - Research Grade (ICH5407), Cifurtilimab Biosimilar - Research Grade (ICH5437), Dalnicastobart Biosimilar - Research Grade (ICH5462), Giloralimab Biosimilar - Research Grade (ICH5571), Iscalimab Biosimilar - Research Grade (ICH5610), Mitazalimab Biosimilar - Research Grade (ICH5689), Ravagalimab Biosimilar - Research Grade (ICH5806), Teneliximab Biosimilar - Research Grade (ICH5915)

https://www.imgt.org/mAb-DB/

ICH3002

P25942

958

RRID:AB_2921576

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD40 antibody selicrelumab, built as a human IgG2-kappa immunoglobulin directed against human CD40 (UniProt P25942). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. The molecule reproduces the antigen-binding specificity of the originator so laboratories can study CD40 engagement in a defined, reproducible reagent. Because selicrelumab is a CD40 agonist antibody, this analog is useful for probing agonistic receptor clustering, downstream signalling, and antigen-presenting-cell activation in vitro, as well as serving as a positive or reference control alongside other anti-CD40 tools and isotype controls. It is well suited to binding and epitope-competition assays, immune-cell activation readouts, and antibody-engineering or format-comparison work. The protein is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low endotoxin option (<0.5 EU/mg), and in bulk milligram-to-gram quantities to support assay development, screening campaigns, and preclinical experimental models requiring consistent lot-to-lot performance. CD40 (TNFRSF5; UniProt P25942) is a type I transmembrane co-stimulatory receptor in the tumour necrosis factor receptor superfamily. It is expressed on antigen-presenting cells including dendritic cells, B lymphocytes, macrophages and monocytes, and also on endothelial and some epithelial and tumour cells. Its ligand, CD40L (CD154), is expressed chiefly on activated CD4+ T cells and platelets. Ligation of CD40 drives receptor clustering and recruitment of TRAF adaptor proteins, activating NF-kappaB, MAPK and other pathways. In B cells this promotes proliferation, germinal-centre formation, immunoglobulin class-switch recombination and affinity maturation; in dendritic cells and macrophages it licenses maturation, upregulates MHC and co-stimulatory molecules, and induces pro-inflammatory cytokines such as IL-12. The CD40/CD40L axis is therefore central to linking innate and adaptive immunity, and agonistic CD40 engagement is of interest for stimulating anti-tumour immune responses.

RO7009789

Detects human CD40. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Selicrelumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Selicrelumab (anti-CD40) Biosimilar

Q: Is the Selicrelumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Selicrelumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Selicrelumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Selicrelumab that binds human CD40.